INTRODUCTION
Tissue factor (TF) is the cell-surface transmembrane receptor that initiates the extrinsic and intrinsic blood coagulation cascades (reviewed by Nemerson [1] , Bach [2] , Edgington et al. [3] and Davie et al. [4] . TF binds Factor VII, promoting its proteolytic conversion into Factor VIIa. Subsequently, the active complex of TF and Factor VITa converts Factors IX into IXa and X into Xa by limited proteolysis, thus triggering the downstream coagulation pathways.
The biochemistry of TF is relevant to haemostasis and to various pathological events. Under normal physiological conditions, it is expressed by extravascular and perivascular cells but not by vascular endothelial cells or leucocytes [5] . On damage to a blood vessel, coagulation factors circulating in the blood come into contact with TF in the perivascular layer, allowing initiation of the coagulation cascades. Although such activation is clearly important in the event of vascular injury, the expression of TF within the vasculature can have catastrophic consequences. Intravascular TF expression has been implicated in thrombosis after atherosclerotic plaque rupture [6] and in disseminated intravascular coagulation (DIC) associated with Gram-negative septic shock [7] . TF antagonists have been demonstrated in animal models to prevent arterial thrombosis [8] , to prevent arterial reclusion after thrombolytic reperfusion therapy [9] and to attenuate DIC [10, 11] . In addition, recent evidence implicates TF as a participant in mediating tumour metastasis in a mouse model [12] . expressed in a non-native state in E. coli inclusion bodies as a fusion protein with a poly(His) leader. The fusion protein could be fully renatured and the leader removed by proteolysis with thrombin; the correct molecular mass (24729 Da) of the purified protein was confirmed by electrospray mass spectrometry. Recombinant tTFs from yeast, E. coli and Chinese hamster ovary cells were identical in their abilities to bind Factor VIIa, to enhance the catalytic activity of Factor VIIa and to enhance the proteolytic activation of Factor X by Factor VIla. Furthermore, CD, fluorescence emission and NMR spectra of the yeast and E. coli proteins indicated that these proteins are essentially identical structurally.
All recognized physiological and pathological effects of TF are attributable to its interactions with Factor VII/VIla to form the functional binary complex, then with substrate zymogens, Factors IX and X in the ternary complex. Thus inhibition of these interactions may be an effective therapeutic strategy to intervene in vascular thrombosis, DIC and tumour metastasis. In order to design such inhibitors, a detailed structural model for the interactions of TF is required.
The deduced amino acid sequence of TF indicates a mature protein of 263 amino acid residues consisting of three distinct domains: an extracellular domain, residues 1-219; a hydrophobic transmembrane domain, residues 220-242; and a cytoplasmic domain, residues 243-263 [13] [14] [15] [16] . The extracellular domain contains two disulphide bonds and three potential N-linked glycosylation sites. The single cysteine of the cytoplasmic tail of human TF carries stearate or palmitate covalently linked via a thioester bond [2] . The abilities of TF to associate with Factor VIIa and to enhance the catalytic and proteolytic activities of Factor VIIa reside primarily in the TF extracellular domain [17] [18] [19] [20] [21] .
Recently, two X-ray-crystal structures of the TF extracellular domain (truncated TF, tTF) have been described [22, 23] . However, no data are yet available on the solution structure and dynamics of tTF and its complex with Factor VITa. As an initial step towards obtaining such information, we have investigated the utility of both Saccharomyces cerevisiae and Escherichia coli expression systems for obtaining milligram quantities of tTF suitable for structural analysis by NMR report here the expression of wild-type tTF and a series of glycosylation-site mutants by yeast and the expression of the wild-type protein in E. coli; efficient incorporation of "5N labels was achieved in both systems. In addition, we describe an efficient method for in vitro renaturation of the E. coli material, and detailed biochemical and physical characterization of proteins from both sources.
EXPERIMENTAL Materials
Strains of S. cerevisiae used were GRY67 (MATa trplA ura3-52) and HMY401 (MATa leu2-3, 112 canlR) which were provided by Dr. David Higgins (Invitrogen, San Diego, CA, U.S.A.). E. coli strains DH5a (Gibco-BRL) and BL21 (Novagen) were used for cloning and fusion protein expression respectively. The E. coli-S. cerevisiae shuttle vector pMFa8 was obtained from American Type Culture Collection, and E. coli-S. cerevisiae shuttle vector pMA91 [24] was provided by Dr. Ian Campbell (Oxford University, Oxford, U.K.); both of these vectors contain genes for replication and maintenance in both E. coli and S. cerevisiae. The E. coli expression vector pTrcHisC was obtained from Invitrogen. Restriction endonucleases, Taq polymerase and DNA ligase were purchased from commercial sources. DNA oligonucleotides were synthesized by The Scripps Research Institute Molecular Biology Core facility. Thrombin was produced by cleavage of prothrombin with Echis carinatus venom and purified by ion-exchange chromatography, as described by Ruf et al. [25] . Growth media used for yeast were YPD and omission media, both described by Rothstein [26] , and minimal medium [1.7 g/l yeast nitrogen base without amino acids or (NH4)2SO4, 20 g/l glucose, 0.5 g/l ('5NH4)2SO4, 5 g/l Na2SO4].
Growth media used for E. coli were LB (10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, 50 mg/l ampicillin) and minimal medium [6.7 g/l Na2HPO4, 3.0 g/l KH2PO4, 1.5 g/l NaCl, 8 g/l glucose, 0.75 g/l (15NH4)2SO4, 0.75 g/l 15NH4C1, 10 mg/l thiamine, 10 mg/l biotin, 50 mg/l ampicillin, 2.86 mg/l boric acid, 25 mg/l CaCl2,2H2O, 0.04 mg/l CoCl2,6H2O, 0.2 mg/l CuSO4,5H20, 208 mg/l MgCl2,6H2O, 0.19 mg/l MnCl2,4H2O, 0.002 mg/l MoO3, 0.208 mg/l ZnCl2, 3.24 mg/l FeCl3].
Construction of yeast expression vectors
The expression vector pMFa8-tTF for the secretion of tTF by yeast under the control of the at-factor promoter was constructed as follows. The cDNA coding for tTF (residues 1-218) was extended and amplified by PCR using the primers 5'-GGGGTA-TCTTTGGATAAAAGATCAGGCACTACAAATACTGTG-3' (5'-primer) and 5'-GCAGCCAAGCTGGCCTCGAAGTTA-TCTGAATTCCCCTTTCTCCTG-3' (3'-primer). The PCR product was cloned into the Stul restriction site of the E. coli-S. cerevisiae shuttle vector pMFaz8 by in vivo homologous recombination in DHSa E. coli [27] . The S. cerevisiae strain GRY697 was transformed with the recombinant plasmid pMFa8-tTF (see Figure 1 ) using the LiCl transformation procedure [26] , and selection of transformants on tryptophandeficient media gave MATa haploids that expressed and secreted tTF.
The expression vector pMA91-tTF for the secretion of tTF by yeast under the control of the phosphoglycerate kinase (PGK) promoter was constructed as follows. The prepro-a-tTF fragment of pMFa8-tTF was amplified by PCR using the primers 5'-ATATAAGGATCCAAAAGAATGAGATTTCC-3' (5'-primer) and 5'-CTTTGACCTGGATCCAAGCTGGCCTCG-3' (3'-primer). The PCR product was cleaved by the restriction enzyme BamHI and ligated into the unique BgllI restriction site on the shuttle vector pMA9 1; recombinant plasmids were isolated after DH5a E. coli transformation. The recombinant vector, pMA91-tTF (see Figure 1) , was used to transform S. cerevisiae strain HMY401 using the LiCl transformation procedure and transformants were selected on leucine-deficient media.
Site-directed mutagenesis
Site-directed mutants in the TF coding sequence cloned into CDM8 were generated by oligonucleotide-directed mutagenesis, as described in detail [19] . Mutants were identified by newly introduced restriction sties. The mutated coding sequence was then subcloned in pMFa8, as described above.
Expression and purification of tTF from yeast Inoculant cultures of GRY697 transformed with the vector pMFa8-tTF or HMY401 transformed with the vector pMA91-tTF were grown by shaking in tryptrophan-or leucine-omission medium respectively at 30°C overnight. Unlabelled samples were prepared using YPD growth medium and "5N-labelled samples were prepared using minimal medium. Inoculant cultures (5 ml) were added to growth medium (1 litre) which were then grown with shaking at 30°C until the cultures reached stationary phase (about 40 h). The cultures were centrifuged [4000 g, 2 h] and the supernatants were filtered consecutively through 1.2 ,um and 0.45 ,um membranes. The pH of the filtrate was adjusted to 7.4-7.5 and PMSF was added to a final concentration of 0.75 mM. The resultant solution was passed at about 1.5 ml/min over an immunoaffinity column loaded with AVIDGEL (BioProbe International, Tustin, CA, U.S.A.)-conjugated to the anti-TF monoclonal antibody TF8-5G9. The column was washed successively with Tris-buffered saline (TBS, pH 7), 1 M NaCl and 0.1 M glycine (pH 4.5), and the protein was eluted with 0.1 M glycine (pH 2.7). Fractions containing protein were pooled, dialysed against 20 mM triethanolamine (TEA, pH 7.5) and loaded on to an HR 10/10 Mono Q anionexchange column. The protein was eluted using a 20 mM TEA buffer containing NaCl at a concentration increasing linearly from 0 to 100 mM over 40 min (flow rate 3 ml/min).
Construction of the E. coll expression vector
The cDNA coding for tTF (residues 1-218) was amplified by PCR using the primers 5'-GAAGAAGGGATCCTGGTGCCT-CGTGGTTCTGGCACTACAAATACT-3' (5'-primer) and 5'-CTGGCCTCAAGCTTAACGGAATTCACCTTT-3' (3'-primer) which allowed the addition of the coding sequence for a thrombin cleavage site upstream ofthe cDNA. The PCR products were cleaved using BamHI and HindIII and ligated between the BamHI and Hindll sites of the expression vector pTrcHisC (Invitrogen). DH5a cells were transformed with the ligation mixture and recombinant plasmids were isolated after selection in the presence of ampicillin. The E. coli strain BL21 was transformed with the recombinant plasmid pTrcHisC-tTF (Figure 1) , and the resultant transformants were used for fusion protein expression.
Expression, refolding and purfficatlon of tTF from E. coli
The poly(His)-tTF fusion protein was expressed using BL21 cells transformed with pTrcHisC-tTF. Inoculant cultures (10 ml in LB medium) were grown overnight with shaking at 37 'C. Unlabelled samples were prepared using LB medium, and 15N-labelled samples were prepared using minimal medium. Inoculant cultures were added to growth medium (1 litre) which were then grown with shaking at 37 'C. When the absorbance at 550 nm had reached about 0.5, 10 ml of 100 mM isopropyl fl-D-thiogalactopyranoside (IPTG) was added. Shaking was continued at 37 'C for about 20 h (to stationary phase).
The cells were harvested by centrifugation (10000 g; 20 min) and the inclusion bodies were isolated as follows (quantities of reagents are per gram of cell paste). The cell paste was suspended in 4 ml of 10 mM Tris/HCl, pH 7.5, containing 150 mM NaCl, 1 mM MgCl2, 0.17 mg/ml PMSF and 2 mg/ml hen's-egg white lysozyme (Sigma). Benzonase (250 units; EM Science) was added and the suspension was mixed gently at room temperature for 1.5 h then centrifuged at 12000 g for 15 min. The pellet was resuspended in 10 mM Tris/HCl, pH 7.5, containing 1 mM EDTA and 3 % Nonidet P40 (2 ml), sonicated for 1 min at 50 % power and centrifuged at 12000 g for 20 min. The pellet was resuspended in water, sonicated for 20-30 s at 50 % power and centrifuged at 12000 g for 20 min. The water wash was repeated and the final pellet, highly enriched for the inclusion bodies, was suspended in buffer containing 6 M guanidinium chloride, 0.5 M NaCl, 20 mM phosphate and 10 mM 2-mercaptoethanol, pH 8 (9 ml/g ofinclusion bodies) by gentle mixing at room temperature overnight. The suspension was centrifuged at 12000 g for 20 min and the supernatant was loaded onto a nickel nitrilotriacetic acid (Ni-NTA; Qiagen) column. The column was washed successively with the same 6 M guanidinium chloride buffer at pH 8 then pH 7, then the protein was eluted by decreasing the pH to 4.
Ni-NTA column fractions containing the fusion protein were combined and dithiothreitol was added to 50 mM. The solution was held at room temperature overnight then diluted to a protein concentration of about 1 mg/ml in 6 M urea/50 mM Tris/ HC1/0.02 % NaN3, pH 8 and dialysed at 4 'C overnight against 10-20 vol. of the same buffer. The buffer was changed to one containing 2 M urea, 50 mM Tris/HCl, 300 mM NaCl, 2.5 mM GSH, 0.5 mM GSSG and 0.02 % NaN3, pH 8 (folding buffer).
Dialysis was continued for 2 days; the buffer was then replaced by fresh folding buffer and dialysis was continued for 2 more days. The solution was then dialysed extensively against 20 mM TEA, pH 7.5, removed from the dialysis bag, treated with human thrombin (about 1 part per 500 parts recombinant protein, w/w) overnight at room temperature, and loaded on to an HR 10/10 Mono Q anion-exchange column. tTF protein was eluted using a 20 mM TEA buffer containing NaCl at a concentration increasing linearly from 0 to 150 mM over 30 min (flow rate 3 ml/min).
Expression and purification of tTF from Chinese hamster ovary (CHO) cells tTF (residues 1-219) was expressed in CHO cells and purified as described previously [17, 28] . 
Amino acid analysis
Protein samples (5-10 jug) were hydrolysed in 6 M HCl/0.01 % phenol/0.05 % 2-mercaptoethanol at 110°C for [20] [21] [22] [23] [24] h, dried in vacuo, then reconstituted in 250 ,s1 of 0.2 M sodium citrate, pH 2.2. Aliquots (50 ,ul) were analysed, by the method of Spackman et al. [29] , on a Beckman model 6300 high-performance analyser modified with a 25 cm-long cation-exchange column for improved resolution.
Electrospray MS Electrospray MS experiments were performed on an API III Perkin-Elmer SCIEX triple-quadruple mass spectrometer. Samples, in 5-10 % acetonitrile, were introduced into the analyser at a rate of 4 1l/min. The positive ions generated by the evaporation process entered the analyser through an interface plate and a 00 #m orifice, and the declustering potential was maintained at 100 V to control the collision energy of the entering ions. The instrument was scanned from m/z 500 to 1500.
ELISA
The concentrations of wild-type or mutant tTF secreted into the culture media by yeast were assessed by an ELISA in which a defined aliquot ofcell-free culture supernatant was serially diluted and subjected to immunoassay based on two monoclonal antibodies to non-overlapping epitopes [19] . SDS/PAGE SDS/PAGE was performed on 12% polyacrylamide gels at 30 mA using the buffer system described by Laemmli [30] . Gels Western-blot analysis Proteins separated by SDS/PAGE (using a Novex 8-16% Tris/glycine gel) were transferred to nitrocellulose using a Janssen SemiDry Electroblotter. After blocking with 50% non-fat dry milk in TBS, membranes were incubated with goat anti-TF (5 /tg/ml) polyclonal IgG fraction for 1 h. After washing in TBS, bound antibody was allowed to react with horseradish peroxidase-conjugated secondary antibody. Addition of the ECL Western-blotting detection reagents (Amersham) gave rise to chemiluminescence which was detected by a 1 min exposure of blue-light-sensitive autoradiography film.
Spectrozyme FXa hydrolysis
The dissociation constant for the interaction of tTF samples with Factor Vlla was measured using Spectrozyme FXa (American Diagnostica, Greenwich, CT, U.S.A.) as the chromogenic substrate for the tTF-Factor VIla complex [17, 18] . To 
Factor X activation
The ability of tTF to enhance the specific proteolytic activation of Factor X by Factor VIIa was assessed as described by Ruf et al. [17] .
CD spectroscopy CD spectra were generated on an Aviv 61DS spectropolarimeter in 1 mm cells at 25°C using a protein concentration of 50,M in 50 mM NaCl/2.5 mM phosphate/50 M EDTA, pH 7. Data were collected at 0.5 nm intervals over the range 260-205 nm with a collection time of 4 s per point and a 1.5 nm bandwidth. Data shown are the average of five scans smoothed using a thirdorder polynomial function over a four-point range.
Fluorescence emission spectroscopy Samples for fluorescence emission spectra were dissolved at 4 mM in 20 mM phosphate/0.5 M NaCl, pH 7.5, containing concentrations ofguanidinium chloride ranging from 0 to 5.85 M. Spectra were generated at 19°C on a SLM Aminco SPF-500C spectrofluorimeter (SLM Instruments) using an excitation wavelength of 290 nm and excitation and emission slit widths of 2 and 7.5 nm respectively. Data were recorded at 1 nm intervals over the range 300-450 nm and were smoothed (three passes) after acquisition. Equilibrium unfolding data were fitted to the two- [31] , and R and T are the universal gas constant and the absolute temperature respectively. This equation assumes that AN and AU do not vary significantly as a function of [D] and that AG varies linearly as a function of [D] .
NMR spectroscopy
Samples for NMR spectroscopy were dissolved at concentrations of 0.5-2 mM in 90 % H20/10 % 2H20 buffer containing 20 mM phosphate, 50 mM NaCl and 0.02 % NaN3. NMR spectra were recorded at 308 K on Bruker AMX500 and AMX600 spectrometers equipped with three-channel interfaces. 'H-"5N heteronuclear single quantum coherence (HSQC) spectra were recorded using the pulse sequence described by Bodenhausen and Ruben [32] and using low-power presaturation for solvent suppression. The 'H carrier was placed on the H20 signal and 1 K complex points were acquired in w2, with a spectral width of 12.5 kHz. In ol, the 15N carrier was placed at 118.0 p.p.m., and 256 real points were collected, with a spectral width of 1600 Hz on the AMX500 or 2000 Hz on the AMX600 spectrometer. Frequency discrimination in w, was achieved by time-proportional phase incrementation [33] . Spectra were processed using a modified version of the FTNMR software (Hare Research). A low-pass filter was applied to suppress residual solvent signal. Window functions used were 10 Hz line-broadening in w2 and a 90°-shifted sine bell in wo.
RESULTS AND DISCUSSION
Expression of wild-type tTF In yeast Wild-type tTF was produced, using the E. coli-S. cerevisiae shuttle plasmid pMFa8-tTF (Figure 1) , in a S. cerevisiae expression system under the control of prepro-a, the leader and signal sequence for yeast ac-mating factor. In this expression system, prepro-ac directs the glycosylation and secretion of native tTF into the culture medium; during the secretory process, the prepro-a sequence is* cleaved from the tTF polypeptide by the KEX2 protease. The prepro-a sequence has been used previously to direct the secretion of a variety of other foreign proteins at expression levels ranging from 10 ,ag/l to 10 mg/l [35] [36] [37] . In the case of tTF the foreign protein was secreted into the culture medium at levels of 5-15 mg/l (see Table 1 ) as assessed by an ELISA using two anti-TF monoclonal antibodies. The expression vector pMFa8-tTF uses the a-factor promoter and terminator sequences for transcription control. In an attempt to increase expression levels, we also expressed tTF using the vector pMA9I -tTF ( Figure 1 ) in which transcription is controlled by the PGK promoter and terminator sequences, considered to promote high levels of transcription in yeast. Changing the promoter did not result in any change in expression levels. Others have reported similar expression levels for tTF (residues 1-217) in yeast using the yeast acid phosphatase promoter and yeast invertase signal sequence [38] . Thus (Figure 2 ). Low-molecular-mass species (apparent molecular masses 37-45 kDa), comprising about 50% of total expressed protein, were probably due to various configurations of core glycosylation only. These were distributed among four discrete bands, presumably corresponding to core glycosylation at different numbers of sites (see discussion of mutants below).
The remaining approx. 50% of the protein was distributed over the apparent molecular-mass range 50-100 kDa, indicating heterogeneous outer-chain glycosylation.
In contrast with our results, tTF (residues 1-217) secreted by yeast strain AH22 (MATa, leu2, his4, canl R, cir+) under the control of the inducible yeast acid phosphatase promoter and the yeast invertase signal sequence [38] was purified as two forms with apparent molecular masses of 150 and 37 kDa; the former was a broad band on SDS/PAGE whereas the latter was highly homogeneous. The 
Expression of glycosylation-deficient tTF mutants in yeast
The high degree of glycosylation and heterogeneity of wild-type tTF secreted by yeast made this material unsuitable for highresolution structural studies by NMR spectroscopy. Therefore several strategies were considered to reduce the level of glycosylation. Complete inhibition of N-linked glycosylation using either tunicamycin or strains of yeast defective in the addition of GlcNAc to proteins was not feasible because N-linked glycosylation within the prepro-a signal sequence is essential for protein processing and secretion [40] [41] [42] . An attempt to reduce the degree of glycosylation by expression of tTF in a yeast strain with the mnn9 mutation, which prevents formation of certain outer-chain mannose-mannose linkages [43] , was unsuccessful. Treatment of immunopurified tTF with jack bean ac-mannosidase [44] resulted in a slight decrease in molecular mass. However, efficient removal of high-molecular-mass mannose chains could not be achieved by this method. Therefore a series of ten mutants was constructed in which one or more of the N-linked glycosylation sites were abolished.
The mutants and their expression levels, as measured by ELISA of the culture supernatants, are listed in Table 1 . There was significant variation in expression levels measured in independent experiments. However, the following trends are evident. (1) The wild-type construct expressed at the highest levels, generally in the range 5-15 mg/I, and mutation of one or Figure 2 . Mutation of either the first or second glycosylation site (lanes 2 and 3) does not significantly reduce the level of outer-chain glycosylation although a clear redistribution of core glycosylation is evident. Mutation of the third site alone (lane 4) essentially eradicates all outer-chain glycosylation, resulting in a protein with two predominant core glycosylated isoforms with apparent molecular masses of approx. 42 (major form) and 38 (minor form) kDa, whereas mutation of the first site in addition to the third (lane 5) yields a protein with just one predominant glycoform of apparent molecular mass about 38 kDa. Simultaneous mutation at all three sites (lane 6) further reduces the apparent molecular mass of the predominant band to about 37 kDa, although the triple mutant expresses at a 10-fold lower level than the T13A,N137D double mutant. The persistence of a minor band at approx. 39 kDa in the triple mutant suggests that tTF contains 0-linked as well as N-linked sugar.
On the basis of observed variations in glycosylation ( Figure 2 ) and expression levels (Table 1) , the T13A,N137D double mutant (denoted tTFT13A.N137D) was selected as being most suitable for NMR structural studies. The predominant form of this mutant runs on SDS/PAGE at about 38 kDa, only slightly higher than the non-glycosylated E. coli protein (see below), and it is available in milligram quantities. This mutant was purified as described above (see Figure 2 , lane 7 and Figure 3, lane 5) ; The N-terminal amino acid sequence was found to be SGTTNT, indicating that cleavage had occurred in the expected position, immediately after the KR sequence of the prepro-a leader, and the amino acid composition was concordant with the composition of tTF. The biological activity and biophysical properties of this mutant were characterized in detail (see below).
Expression of tTF in E. coli and in vitro renaturation tTF was expressed as a fusion protein in E. coli using the expression vector pTrcHisC-tTF ( Figure 1 ). The fusion protein (258 amino acids, 29.2 kDa) consisted of: (i) a (His)6 sequence, to allow ready purification by nickel-affinity chromatography; (ii) an immunoreactive tag, to allow ready identification of the fusion protein; (iii) consecutive enterokinase-and thrombincleavage sites; and (iv) residues 1-218 of TF. This fusion protein was expressed at about 50 mg/I, the most abundant cellular protein ( Figure 3 , lane 2), and was localized in inclusion bodies. The inclusion bodies could be solubilized in denaturing buffer and purified to approx. 95 % purity ( Figure 3, lane 3) by nickelaffinity chromatography. Efficient renaturation of the affinity-purified fusion protein was highly dependent on the buffer conditions used. Renaturation was expected to be limited by the rate of formation of the correct disulphide bonds (Cys29-Cys57 and Cys186-Cys209). Thus folding was performed at pH 8 in the presence of a redox exchange buffer containing a mixture of GSH and GSSG, under which conditions disulphide exchange is expected to be rapid. Guanidinium chloride (1.4-2.0 M) or urea (2-5 M) provided conditions under which the denatured material remained soluble, but the native state was more stable than the denatured state (see Figure  6d ). Under such conditions the protein does not aggregate, thereby allowing the system to reach equilibrium with the native structure predominant. Refolding was also favoured by low temperature (4°C) and about 300 mM NaCl. This is the first description of conditions for the efficient in vitro renaturation of TF.
After refolding, the fusion protein could be cleaved by proteolysis with thrombin. It was necessary to perform the refolding before the cleavage because thrombin is denatured at the concentration of denaturant required to maintain solubility of the non-native fusion protein. The thrombin cleavage was highly efficient, being more than 90 % complete after incubation of 1 part fusion protein with approx. 0.002 parts (w/w) thrombin at room temperature overnight. Furthermore, there was no evidence of any cleavage within the TF sequence, in line with predictions based on published guidelines for amino acid sequence susceptibilities to thrombin cleavage [45] . The thrombin cleaved between the Arg and Gly of the sequence Leu-Val-Pro-Arg-Gly-Ser*, in which Ser* is not only the final amino acid of the published thrombin-cleavage site [46] but also residue 1 of TF. Thus thrombin-cleavage leaves an additional Gly at the N-terminus of tTF. The cleavage site was confirmed by N-terminal amino acid sequencing of the ion-exchange-purified cleavage product; the N-terminal sequence was found to be GSGTTNTVA, as expected. The amino acid composition of the product was also concordant with the expected sequence.
The apparent molecular mass of the purified protein by SDS/PAGE is 35 kDa (Figure 3, lane 4) [17, 18] . Monitoring the rate of Spectrozyme FXa cleavage as a function of tTF concentration allows measurement of the apparent dissociation constant for the interaction of tTF and Factor VIla [21] (Figure 4a ). Using this assay, the Kd for tTF expressed in CHO cells, yeast (T13A,N137D mutant) and E. coli were found to be 2.8, 5.3 and 3.8 nM respectively, indicating that, within the accuracy of the experiments, these tTF molecules are identical in their abilities to bind to and activate Factor VIIa. Furthermore, the maximum catalytic rates of the tTF-Factor VIIa complexes at saturation were also identical for all three constructs (Figure 4a) , suggesting that the essential components of the enzyme (Factor VIIa)-cofactor (tTF) interaction are retained in the proteins from the various expression systems.
A wide variation of dissociation constants for the TF-Factor VITa interaction has been reported previously (summarized by O'Brien et al. [48] . In particular, Shigematsu et al. [38] Second, -the ability of the complex between tTF and Factor VITa to convert Factor X into Factor Xa was assessed. Although the cleavage of Factor X is accelerated significantly by membrane association of both the catalytic complex and Factor X, the complex between tTF and Factor VITa still cleaves Factor X at a significant rate [17, 18] . Figure 4( glycosylation adds 10-20 kDa to the molecular mass [17] . In contrast, the E. coli material carries no sugar residues. The identical biological activity of these proteins indicates that glycosylation does not influence tTF interaction with Factor Vlla or Factor X. This is consistent with previous results reported for full-length TF [47] . The function, if any, of TF glycosylation remains unknown; possible functions include protection from degradation by proteases, facilitation of secretory mechanisms and protection from undesirable protein-protein interactions. CD spectra tTF proteins from yeast and E. coli exhibit very similar CD spectra ( Figure 5 ) with maxima at 233 nm, minima at 209-211 nm and negative shoulders at about 216 nm. The slight intensity difference observed ( Figure 5 ) is within the experimental error which may be estimated on the basis of uncertainty of sample concentration measurements. These spectra are not typical of either cc-helical or f-sheet proteins but the weak intensity suggests that there is minimal, if any, a-structure present [49] , consistent with the prediction that TF is a distant member of the fl-structured cytokine receptor superfamily [50] .
This prediction was confirmed recently by X-ray-crystallographic analysis [22, 23] . The source of the dominant CD absorbance is most likely either aromatic or disulphide groups in chiral environments, presumably in the hydrophobic protein core [51] .
Fluorescence emission spectra tTF contains four tryptophan residues. Both E. coli tTF and tTFT13A N137D from yeast give intense fluorescence spectra ( Figure   6 ) typical of tryptophan-containing proteins [52] . For NMR spectra tTF produced in either the yeast or E. coli expressed system could be uniformly enriched with 15N using expression media in which the sole source of nitrogen was "5N-enriched ammonium salts. The "5N-HSQC NMR spectra of uniformly "5N-labelled tTF from E. coli and tTFT13A,Nl37D from yeast are shown in Figure 7 . These spectra correlate directly bonded pairs of 'H and 15N nuclei, and the positions of the cross-peaks in such spectra provide a fingerprint for the tertiary protein structure. Thus the correspondence between peak positions in the two spectra provides strong evidence that tTF from E. coli and tTFT13A,N137D from yeast have essentially the same tertiary structure. The few minor differences observed are most likely due to minor structural differences at or adjacent to the two mutation sites or near any remaining glycosylation site(s) in the yeast protein. In 
